CTNI-66. ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Primary central nervous system lymphoma (PCNSL) is known as one of the incurable brain tumors. In March 2020, Tirabrutinib (TIR), a second-generation oral Bruton’s tyrosine kinase inhibitor, was approved for the indication of relapsed or refractory PCNSL (rrPCNSL) based on the results of a phase I/I...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Mishima, Kazuhiko, Narita, Yoshitaka, Nagane, Motoo, Terui, Yasuhito, Arakawa, Yoshiki, Yonezawa, Hajime, Asai, Katsunori, Fukuhara, Noriko, Sugiyama, Kazuhiko, Shinojima, Naoki, Aoi, Arata, Nishikawa, Ryo
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Clinical Trials: Non-Immunologic
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650894/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.232
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki